Molecular structure of Pomalidomide, CAS Number: 19171-19-8
Pomalidomide (CAS 19171-19-8)
See product citations (1)
Alternate Names:
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Application:
Pomalidomide is an inhibitor of LPS-induced TNFαrelease
CAS Number:
19171-19-8
Purity:
≥99%
Molecular Weight:
273.24
Molecular Formula:
C13H11N3O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Pomalidomide is a chemical of interest in the field of molecular biology and immunology, particularly for its role as an immunomodulatory agent. Research involving pomalidomide often centers on its mechanism of action in the modulation of the immune response through the inhibition of pro-inflammatory cytokines and the stimulation of anti-inflammatory cytokines. Studies also delve into its impact on cellular processes, such as the inhibition of angiogenesis and the alteration of the microenvironment that supports the survival of certain cells. In addition, pomalidomide′s influence on the expression of adhesion molecules and the interaction with the cereblon protein complex are key mechanisms under investigation, which are thought to affect a range of cellular functions.
Pomalidomide (CAS 19171-19-8) References
- Pomalidomide-induced hypothyroidism. | Ali, SH., et al. 2017. Endocrinol Diabetes Metab Case Rep. 2017: PMID: 29302330
- Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. | Fujiwara, Y., et al. 2018. Cancer Res. 78: 6655-6665. PMID: 30315115
- Pomalidomide in lenalidomide-refractory multiple myeloma: Far from futile. | Mo, CC. and Richardson, PG. 2020. Br J Haematol. 188: 483-485. PMID: 31566715
- Pomalidomide desensitization for hypersensitivity: A case report. | Park, JJ., et al. 2020. J Oncol Pharm Pract. 26: 1244-1247. PMID: 31822201
- Crystal structure of the SALL4-pomalidomide-cereblon-DDB1 complex. | Matyskiela, ME., et al. 2020. Nat Struct Mol Biol. 27: 319-322. PMID: 32251415
- Pomalidomide and dexamethasone in myelomatous pleural effusion. | Comba, IY., et al. 2020. BMJ Case Rep. 13: PMID: 33303498
- Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. | Gooding, S., et al. 2021. Blood. 137: 232-237. PMID: 33443552
- Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma. | Mark, T., et al. 2022. Future Oncol. 18: 553-564. PMID: 34787472
- Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson's Disease. | Palmas, MF., et al. 2022. Neurotherapeutics. 19: 305-324. PMID: 35072912
- Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. | Matsue, K., et al. 2022. Int J Hematol. 116: 122-130. PMID: 35429329
- Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFRWT and EGFRT790M. | O Aboelez, M., et al. 2022. J Enzyme Inhib Med Chem. 37: 1196-1211. PMID: 35470756
- Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. | Sonneveld, P., et al. 2022. Hemasphere. 6: e786. PMID: 36204691
- Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients-Real-World Data From Hungary. | Lovas, S., et al. 2022. Pathol Oncol Res. 28: 1610645. PMID: 36262875
- Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients. | Wang, X., et al. 2022. Front Pharmacol. 13: 1076096. PMID: 36545316
- Pomalidomide-induced lung injury: A case report. | Vivien, A., et al. 2023. Medicine (Baltimore). 102: e32473. PMID: 36637962
Inhibitor of:
AHSP, Apg12, APRIL-TWEAK, ARMC6, Axotrophin, Baff, BAI-1, CD3EAP, CRBN, CS1, DCAF15, DCAF17, Dcun1D1, DTX3L, EndoV, Erythroid lineage, Hemoglobin β, Hemoglobin ε, Ig κ chain, Ig κ light chain, Ikaros, IRF-4, KIAA1984, KLHDC6, KLHL21, Klra22, MAGE-C2, MARCH (membrane associated ring-CH-type finger), MIB1, Olr704, PCNP, Plasma Cell, Rbx1, RNF113A2, RNF126, RNF220, RNF6, Rsl2, Rslcan-14, TALL-1, TNF alpha, TRIM34B, TTC30A2, TWEAK, UBCE7IP4, WDR21C, WDSOF1, and WDYHV1.Activator of:
ASB-8, B7-H6, BAFF-R, BCMA, BTBD18, c-IAP2, CD137L, CD223, Cdc53, CLEC-2, CT47A12, CUL-2, DcR3, Dcun1D3, E6-AP, F830116E18Rik, Hbb-b2, Hemoglobin, Hemoglobin γ, KLHL9, LSP1, MAGE-B3, MARCH3, NKp46, RELL2, RFPL2, RNF141, RNF23, Skeletrophin, TRIM69, TROY, UBC12, UBC8, UBE2O, UBE2S, UBE2U, UBE2Z, UCH-L5, USP17L4, USP17L7, USP17L8, USP9Y, and WDR21A.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Pomalidomide, 5 mg | sc-364593 | 5 mg | $100.00 | |||
Pomalidomide, 10 mg | sc-364593A | 10 mg | $143.00 | |||
Pomalidomide, 50 mg | sc-364593B | 50 mg | $312.00 | |||
Pomalidomide, 100 mg | sc-364593C | 100 mg | $468.00 | |||
Pomalidomide, 500 mg | sc-364593D | 500 mg | $1248.00 | |||
Pomalidomide, 1 g | sc-364593E | 1 g | $1997.00 |